Kristi Rosa

Associate Editorial Director, OncLive®
Kristi Rosa joined MJH Life Sciences in 2016 and has since held several positions within the company. She helped launch the rapidly growing infectious disease news resource Contagion, strengthened the Rare Disease Report, of HCPLive, and now oversees OncLive and its flagship publication OncologyLive. Prior to working at the company, she served as lead copywriter and marketing coordinator at The Strand Theater. Email: krosa@onclive.com

Articles

Dr Beck on the FDA Approval of Subcutaneous Pembrolizumab in Solid Tumors

September 25th 2025

J. Thaddeus Beck, MD, FACP, discusses the FDA approval of subcutaneous pembrolizumab and berahyaluronidase for use across all adult and solid-tumor indications.

A400/EP0031 NDA Accepted for Review in China for RET Fusion–Positive NSCLC

September 25th 2025

China’s NMPA has accepted for review a new drug application for A400/EP0031 in patients with RET fusion–positive non–small cell lung cancer.

SHR-4849 Shows Preliminary Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025

SHR-4849 showed acceptable safety and early antitumor activity in relapsed small cell lung cancer.

SHR-4849 Shows Activity With Manageable Safety in Relapsed Small Cell Lung Cancer

September 18th 2025

SHR-4849 showed acceptable safety and preliminary antitumor activity in relapsed small cell lung cancer.

KN026 NDA in Pretreated HER2+ Gastric or GEJ Cancer Accepted by NMPA for Review

September 17th 2025

The NDA seeking approval of KN026 plus chemotherapy in HER2-positive gastric or GEJ cancer has been accepted for review in China.

Rezatapopt Elicits Responses in Several Solid Tumors Harboring a TP53 Y220C Mutation

September 15th 2025

Updated PYNNACLE data show activity of rezatapopt in TP53 Y220C–mutated solid tumors.

Nadofaragene Firadenovec NDA Accepted for Review in Japan for BCG-Unresponsive NMIBC

September 15th 2025

A new drug application for nadofaragene firadenovec in BCG-unresponsive bladder cancer has been accepted for review in Japan.

IDE397 Plus Sacituzumab Govitecan Elicits Responses in MTAP-Deletion Urothelial Cancer

September 15th 2025

IDE397 plus sacituzumab govitecan shows preliminary efficacy in MTAP-deletion urothelial cancer.

Tarlatamab Plus Anti–PD-L1 as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Tarlatamab Plus Anti–PD-L1 Therapy as Frontline Maintenance Shows Unprecedented OS in ES-SCLC

September 15th 2025

Tarlatamab plus anti–PD-L1 therapy as frontline maintenance shows acceptable safety and unprecedented survival in extensive-stage SCLC.

Expert-Backed Roadmap Guides Outpatient Bispecific Antibody Use in Myeloma

September 14th 2025

A roadmap shares guidelines for the safe administration of bispecific antibodies to patients with multiple myeloma in outpatient and community settings.

Five Under 5: Top Oncology Videos for the Week of 9/7

September 14th 2025

The top 5 OncLive TV videos of the week cover insights in lung cancer, non–muscle-invasive bladder cancer, and colorectal cancer.

The OncFive: Top Oncology Articles for the Week of 9/7

September 13th 2025

The FDA has approved TAR-200 in urothelial cancer and selumetinib in pediatric NF-1–associated inoperable plexiform neurofibromas, and more.

Trastuzumab Pamirtecan Hits Phase 3 PFS End Point in HER2+ Metastatic Breast Cancer

September 12th 2025

Trastuzumab pamirtecan improved progression-free survival in HER2-positive advanced breast cancer after prior trastuzumab and taxane-based chemotherapy.

Bexobrutideg Shows Early Promise in BTK- and BCL2-Exposed, Relapsed/Refractory CLL

September 12th 2025

The novel BTK degrader led to fast-onset responses that were maintained over time in patients with CLL/SLL.

Orelabrutinib Receives Approval in Singapore for Marginal Zone Lymphoma

September 11th 2025

Orelabrutinib has been approved as a treatment option for patients with marginal zone lymphoma in Singapore.

Relacorilant NDA Is Under FDA Review for Platinum-Resistant Ovarian Cancer

September 10th 2025

The FDA accepted a NDA for relacorilant in platinum-resistant ovarian cancer based on data from ROSELLA and other phase 2 trials.

Repotrectinib Demonstrates Durable Efficacy in TKI-Naive and -Pretreated ROS1+ NSCLC

September 10th 2025

Repotrectinib elicited durable responses, including intracranial responses, in TKI-naive and -pretreated patients with NSCLC.

Cemiplimab Plus Chemotherapy Provides Long-Term Survival Benefit in Advanced NSCLC

September 10th 2025

Five-year data show cemiplimab plus chemotherapy delivers durable OS, ORR, and DOR benefits in advanced NSCLC.

SKYSCRAPER-05 Data Confirm Surgical Feasibility After Perioperative Tiragolumab Combo in NSCLC

September 9th 2025

The SKYSCRAPER-05 trial shed light on the use of perioperative tiragolumab plus atezolizumab with or without chemotherapy in NSCLC.